Imaging in Stem Cell Transplant and Cell-based Therapy

84

30. Barlogie B, Jagannath S, Desikan KR, Mattox S, Vesole D, Siegel D, et al. Total therapy with
    tandem transplants for newly diagnosed multiple myeloma. Blood. 1999;93(1):55–65.


31. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, et al. A prospective, ran­
    domized trial of autologous bone marrow transplantation and chemotherapy in multiple
    myeloma. Intergroupe Français du Myélome. N Engl J Med. 1996;335(2):91–7.


32. Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K, et al. High­dose chemo­
    therapy with hematopoietic stem­cell rescue for multiple myeloma. N Engl J  Med.
    2003;348(19):1875–83.


33. Rajkumar SV, Gahrton G, Bergsagel PL. Approach to the treatment of multiple myeloma: a
    clash of philosophies. Blood. 2011;118(12):3205–11.


34. Cavo M, Pantani L, Pezzi A, Petrucci MT, Patriarca F, Di Raimondo F, et  al. Bortezomib­
    thalidomide­ dexamethasone (VTD) is superior to bortezomib­cyclophosphamide­
    dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in
    multiple myeloma. Leukemia. 2015;29(12):2429–31.


35. Ludwig H, Greil R, Masszi T, Spicka I, Shpilberg O, Hajek R, et al. Bortezomib, thalidomide
    and dexamethasone, with or without cyclophosphamide, for patients with previously untreated
    multiple myeloma: 5­year follow­up. Br J Haematol. 2015;171(3):344–54.


36. Moreau P, Hulin C, Macro M, Caillot D, Chaleteix C, Roussel M, et al. VTD is superior to
    VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013­04
    trial. Blood. 2016 Mar 21. pii: blood­2016­01­693580.


37. Sonneveld P, Goldschmidt H, Rosiñol L, Bladé J, Lahuerta JJ, Cavo M, et  al. Bortezomib­
    based versus nonbortezomib­based induction treatment before autologous stem­cell transplan­
    tation in patients with previously untreated multiple myeloma: a meta­analysis of phase III
    randomized, controlled trials. J Clin Oncol. 2013;31(26):3279–87.


38. Stewart AK, Jacobus S, Fonseca R, Weiss M, Callander NS, Chanan­Khan AA, et  al.
    Melphalan, prednisone, and thalidomide vs melphalan, prednisone, and lenalidomide (ECOG
    E1A06) in untreated multiple myeloma. Blood. 2015;126(11):1294–301.


39. Zweegman S, van der Holt B, Mellqvist UH, Salomo M, Bos GM, Levin MD, et al. Melphalan,
    prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated
    multiple myeloma. Blood. 2016;127(9):1109–16. doi:10.1182/blood­2015­11­679415.. Epub
    2016 Jan 22.


40. Gay F, Oliva S, Petrucci MT, Conticello C, Catalano L, Corradini P, et al. Chemotherapy plus
    lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone
    versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicen­
    tre, phase 3 trial. Lancet Oncol. 2015;16(16):1617–29.


41. Attal M, Harousseau JL, Facon T, Guilhot F, Doyen C, Fuzibet JG, et al. Single versus double
    autologous stem­cell transplantation for multiple myeloma. N Engl J  Med. 2003;349(26):
    2495–502.


42. Cavo M, Tosi P, Zamagni E, Cellini C, Tacchetti P, Patriarca F, et al. Prospective, randomized
    study of single compared with double autologous stem­cell transplantation for multiple
    myeloma: Bologna 96 clinical study. J Clin Oncol. 2007;25(17):2434–41.


43. Kumar A, Kharfan­Dabaja MA, Glasmacher A, Djulbegovic B. Tandem versus single autolo­
    gous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic
    review and meta­analysis. J Natl Cancer Inst. 2009;101(2):100–6.


44. Kumar S, Giralt S, Stadtmauer EA, Harousseau JL, Palumbo A, Bensinger W, et al. Mobilization
    in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial
    therapy with thalidomide­, lenalidomide­, or bortezomib­containing regimens. Blood. 2009;
    114(9):1729–35.


45. Naumann­Winter F, Greb A, Borchmann P, Bohlius J, Engert A, Schnell R. First­line tandem
    high­dose chemotherapy and autologous stem cell transplantation versus single high­dose
    chemotherapy and autologous stem cell transplantation in multiple myeloma, a systematic
    review of controlled studies. Cochrane Database Syst Rev. 2012;10:CD004626.


46. Grövdal M, Nahi H, Gahrton G, Liwing J, Waage A, Abildgaard N, et al. Autologous stem cell
    transplantation versus novel drugs or conventional chemotherapy for patients with relapsed
    multiple myeloma after previous ASCT. Bone Marrow Transplant. 2015;50(6):808–12.

S. Thanendrarajan and T.K. Garg